Pharmacological effects of lysozyme on COPD and bronchial asthma with sputum: A randomized, placebo-controlled, small cohort, cross-over study

• Published in: Pulmonary pharmacology & therapeutics 2016-04, Vol.37, p.73-80
• Main Authors: Ohbayashi, Hiroyuki, Setoguchi, Yasuhiro, Fukuchi, Yoshinosuke, Shibata, Kai, Sakata, Yukinori, Arai, Toshihisa
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Asthma - drug therapy; Asthma - physiopathology; Bronchial asthma (BA); Chronic obstructive pulmonary disease (COPD) management; Cross-Over Studies; Double-Blind Method; Dyspnea - drug therapy; Dyspnea - etiology; Expectorants - administration & dosage; Expectorants - adverse effects; Expectorants - pharmacology; Female; Humans; Impulse oscillometry system (IOS); Lysozyme; Male; Medical Education; Middle Aged; Mucolytic agent; Muramidase - administration & dosage; Muramidase - adverse effects; Muramidase - pharmacology; Nitric Oxide - metabolism; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - physiopathology; Pulmonary/Respiratory; Quality of Life; Spirometry; Sputum - metabolism; Treatment Outcome
• ISSN: 1094-5539; 1522-9629
• DOI: 10.1016/j.pupt.2016.03.001

Abstract Background Mucolytic agents are often used in Japan to ease excessive mucus production in patients with chronic obstructive pulmonary disease (COPD) or bronchial asthma (BA); the treatment ameliorates dyspnea and improves quality of life (QOL). Aim Efficacy and safety of lysozyme hydrochloride (LYS), an oral mucolytic enzyme preparation, for patients with COPD or BA were investigated. Patients and methods This study was a placebo-controlled, double-blind, randomized, cross-over design. Twenty-four patients with COPD and twenty-four patients with BA were enrolled. LYS or placebo was administered for 28 days in each treatment period, with a 28-day washout between the first and second treatment periods. The results of spirometry, impulse oscillometry system (IOS) examination, fractional exhaled nitric oxide (FeNO) measurement, as well as the changes in the subjective symptoms, were evaluated after the treatment period. Results On spirometry, airway function (FEV1) improved in patients with COPD after administration of LYS (LYS vs placebo: 0.08 L vs 0.029 L, p = 0.030). Similar trends were also found in %FEV1 in COPD patients. On IOS examination, resistance of the respiratory system at 5 Hz levels was significantly improved only in patients with COPD (LYS vs placebo: −0.455 cm H2 O/L/s vs 0.095 cmH2 O/L/s, p = 0.012). Similar trends were found in terms of the resistance of the respiratory system at 20 Hz, and of the reactance area. In the COPD assessment test, subjective symptoms also significantly improved in patients with COPD during the LYS treatment period (improvement rates—LYS vs . placebo: 69.6% vs . 39.1%; p = 0.022). A similar effect of LYS was not seen in BA patients. Conclusion LYS, a mucolytic agent, has capability to improve the function of peripheral airways in patients with COPD, which leads to improvements of the patients' symptoms and QOL.